Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 14/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | ATR | Q13535 | 2/20 | 0.39 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.39 |
| ▸ | SMO | Q99835 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16025532 | 0.90 | LRRK2 (0.47) | LRRK2ABL1SMOPIK3CA | |
| SCHEMBL16014153 | 0.89 | LRRK2 (0.47) | LRRK2ABL1ATRATRIP | |
| SCHEMBL16014230 | 0.88 | LRRK2 (0.57) | LRRK2ATRATRIP | |
| SCHEMBL16025554 | 0.88 | LRRK2 (0.39) | LRRK2ABL1ATRATRIPSMO | |
| SCHEMBL16025794 | 0.87 | LRRK2 (0.45) | LRRK2ATRATRIPPIK3CA | |
| SCHEMBL16014229 | 0.86 | LRRK2 (0.42) | LRRK2ATRATRIPSMOPIK3CA | |
| SCHEMBL17432533 | 0.85 | LRRK2 (0.43) | LRRK2SMOPIK3CA | |
| SCHEMBL16025372 | 0.85 | LRRK2 (0.44) | LRRK2ABL1SMOPIK3CA | |
| SCHEMBL17432520 | 0.84 | LRRK2 (0.41) | LRRK2ABL1SMOPIK3CA | |
| SCHEMBL17416819 | 0.84 | ABL1 (0.45) | LRRK2ABL1ATRATRIPSMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964221-B1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME (US) | 2017-12-06 | — | — | EP | disclosed |
| US-9440952-B2 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | MERCK SHARP & DOHME CORP. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440952-B2 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | MERCK SHARP & DOHME CORP. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20160009682-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME LLC | 2016-01-14 | — | — | US | disclosed |
| US-20160009682-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME LLC | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009682-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | LRRK2, LRRC47, LIMK2 | LRRK2 1/4885ABL1 352/4885ATR 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.